Topically applied mometasone furoate improves dysphagia in adult eosinophilic esophagitis – results from a double-blind, randomized, placebo-controlled trial

References

• Straumann A. Medical therapy in eosinophilic oesophagitis. Best Pract Res Clin Gastroenterol. 2015;29(5):805–814.
   PubMed Web of Science ®Google Scholar
• Alexander JA, Jung KW, Arora AS, et al. Swallowed fluticasone improves histologic but not symptomatic response of adults with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2012;10(7):742–749 e1.
   PubMed Web of Science ®Google Scholar
• Miehlke S. Clinical features of Eosinophilic esophagitis in children and adults. Best Pract Res Clin Gastroenterol. 2015;29(5):739–748.
   PubMed Web of Science ®Google Scholar
• Butz BK, Wen T, Gleich GJ, et al. Efficacy, dose reduction, and resistance to high-dose fluticasone in patients with eosinophilic esophagitis. Gastroenterology. 2014;147(2):324–333 e5.
   PubMed Web of Science ®Google Scholar
• Konikoff MR, Noel RJ, Blanchard C, et al. A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis. Gastroenterology. 2006;131(5):1381–1391.
   PubMed Web of Science ®Google Scholar
• Straumann A, Conus S, Degen L, et al. Budesonide is effective in adolescent and adult patients with active eosinophilic esophagitis. Gastroenterology. 2010;139(5):1526–1537 e1.
   PubMed Web of Science ®Google Scholar
• Schlag C, Miehlke S, Heiseke A, et al. Peripheral blood eosinophils and other non-invasive biomarkers can monitor treatment response in eosinophilic oesophagitis. Aliment Pharmacol Ther. 2015;42(9):1122–1130.
   PubMed Web of Science ®Google Scholar
• Lucendo AJ, Miehlke S, Schlag C, et al. Efficacy of budesonide orodispersible tablets as induction therapy for eosinophilic esophagitis in a randomized placebo-controlled trial. Gastroenterology. 2019;157(1):74–86 e15.
   PubMed Web of Science ®Google Scholar
• Sastre J, Mosges R. Local and systemic safety of intranasal corticosteroids. J Investig Allergol Clin Immunol. 2012;22(1):1–12.
   PubMed Web of Science ®Google Scholar
• Larsson H, Bergman K, Finizia C, et al. Dysphagia and health-related quality of life in patients with eosinophilic esophagitis: a long-term follow-up. Eur Arch Otorhinolaryngol. 2015;272(12):3833–3839.
   PubMed Web of Science ®Google Scholar
• Bergquist H, Larsson H, Johansson L, et al. Dysphagia and quality of life may improve with mometasone treatment in patients with eosinophilic esophagitis: a pilot study. Otolaryngol Head Neck Surg. 2011;145(4):551–556.
   PubMed Web of Science ®Google Scholar
• Syverson EP, Hait E, McDonald DR, et al. Oral viscous mometasone is an effective treatment for eosinophilic esophagitis. J Allergy Clin Immunol Pract. 2019;8(3):P1107–P1109.
   PubMed Web of Science ®Google Scholar
• Dakkak M, Bennett JR. A new dysphagia score with objective validation. J Clin Gastroenterol. 1992;14(2):99–100.
   PubMed Web of Science ®Google Scholar
• Kostic S, Kjellin A, Ruth M, et al. Pneumatic dilatation or laparoscopic cardiomyotomy in the management of newly diagnosed idiopathic achalasia. Results of a randomized controlled trial. World J Surg. 2007;31(3):470–478.
   PubMed Web of Science ®Google Scholar
• Bergquist H, Andersson M, Ejnell H, et al. Functional and radiological evaluation of free jejunal transplant reconstructions after radical resection of hypopharyngeal or proximal esophageal cancer. World J Surg. 2007;31(10):1988–1995.
   PubMed Web of Science ®Google Scholar
• Blazeby JM, Conroy T, Hammerlid E, et al. Clinical and psychometric validation of an EORTC questionnaire module, the EORTC QLQ-OES18, to assess quality of life in patients with oesophageal cancer. Eur J Cancer. 2003;39(10):1384–1394.
   PubMed Web of Science ®Google Scholar
• Blazeby JM, Alderson D, Winstone K, et al. Development of an EORTC questionnaire module to be used in quality of life assessment for patients with oesophageal cancer. The EORTC Quality of Life Study Group. Eur J Cancer. 1996;32(11):1912–1917.
   Web of Science ®Google Scholar
• Sullivan M, Karlsson J, Ware JE. Jr., The Swedish SF-36 Health Survey–I. Evaluation of data quality, scaling assumptions, reliability and construct validity across general populations in Sweden. Soc Sci Med. 1995;41(10):1349–1358.
   PubMed Web of Science ®Google Scholar
• Lingblom C, Bergquist H, Johnsson M, et al. Topical corticosteroids do not revert the activated phenotype of eosinophils in eosinophilic esophagitis but decrease surface levels of CD18 resulting in diminished adherence to ICAM-1, ICAM-2, and endothelial cells. Inflammation. 2014;37(6):1932–1944.
   PubMed Web of Science ®Google Scholar
• Taft TH, Kern E, Kwiatek MA, et al. The adult eosinophilic oesophagitis quality of life questionnaire: a new measure of health-related quality of life. Aliment Pharmacol Ther. 2011;34(7):790–798.
   PubMed Web of Science ®Google Scholar
• Dellon ES, Irani A-M, Hill MR, et al. Development and field testing of a novel patient-reported outcome measure of dysphagia in patients with eosinophilic esophagitis. Aliment Pharmacol Ther. 2013;38(6):634–642.
   PubMed Web of Science ®Google Scholar
• Lucendo AJ, et al. Transcultural adaptation and validation of the “Adult Eosinophilic Esophagitis Quality of Life Questionnaire” into Spanish. Rev Esp Enferm Dig. 2014;106(6):386–394.
   PubMed Web of Science ®Google Scholar
• Dellon ES, Woosley JT, Arrington A, et al. Efficacy of budesonide vs fluticasone for initial treatment of eosinophilic esophagitis in a randomized controlled trial. Gastroenterology. 2019;157(1):65–73 e5.
   PubMed Web of Science ®Google Scholar
• Larsson H, Norder Grusell E, Tegtmeyer B, et al. Grade of eosinophilia versus symptoms in patients with dysphagia and esophageal eosinophilia. Dis Esophagus. 2016;29(8):971–976.
   PubMed Web of Science ®Google Scholar